Skip to content

Medical emergency? What to do

Herceptin very effective in HER2+ breast cancer

3-RXPublished October 20, 20053 min read

Key points

  • Two studies published in The New England Journal of Medicine show that treatment with trastuzumab (Herceptin; Roche) can dramatically improve outcomes in women with breast cancers that are HER2-positive.
  • Piccart-Gebhart and members of the Herceptin Adjuvant (HERA) Trial Study Team enrolled patients with HER2-positive, early stage breast cancer who underwent surgery to removed the tumor and at least four cycles of chemotherapy.
  • "This degree of benefit in early breast cancer is the largest to be reported since the introduction of tamoxifen in hormone-receptor-positive disease," the authors note.
  • Piccart-Gebhart's team advises that 1 year of Herceptin should be considered a standard option after surgery or chemotherapy in women who fulfill the eligibility criteria used in this trial.

Two studies published in The New England Journal of Medicine show that treatment with trastuzumab (Herceptin; Roche) can dramatically improve outcomes in women with breast cancers that are HER2-positive.

HER2 overexpression occurs in approximately 15 percent to 25 percent of breast cancers and is associated with a worse prognosis than HER2-negative tumors.

Dr. Martine J. Piccart-Gebhart and members of the Herceptin Adjuvant (HERA) Trial Study Team enrolled patients with HER2-positive, early stage breast cancer who underwent surgery to removed the tumor and at least four cycles of chemotherapy. A total of 1,694 women were then assigned to 1 year of treatment with Herceptin, a humanized monoclonal antibody, and 1,693 patients were assigned to observation only.

At 1-year follow-up, there were 127 events, including recurrence of breast cancer, breast cancer in the other breast, or a second malignant disease in the Herceptin group and 220 in the observation group, a statistically significant difference. Mortality rates were similar in the two groups.

"This degree of benefit in early breast cancer is the largest to be reported since the introduction of tamoxifen in hormone-receptor-positive disease," the authors note.

There were more serious adverse events (7.0 percent versus 4.7 percent) among women given Herceptin than in those in the comparison group. Symptomatic heart failure developed in 1.73 percent in the Herceptin group and 0.06 percent in the observation group.

Piccart-Gebhart's team advises that 1 year of Herceptin should be considered a standard option after surgery or chemotherapy in women who fulfill the eligibility criteria used in this trial.

In a second paper in the Journal, Dr. Charles E. Geyer, Jr., at the Allegheny Cancer Center in Pittsburgh, and colleagues present combined results of the National Surgical Adjuvant Breast and Bowel Project trial B-31 and the North Central Cancer Treatment Group trial N9831. The two studies were amended to include a joint analysis.

Following tumor removal, patients in both groups were treated with doxorubicin and cyclophosphamide followed by paclitaxel. One group of 1,679 patients then received Herceptin for 1 year. There were 1,672 patients who followed the same course of treatment but received concomitant paclitaxel and Herceptin for 1 year.

During a follow-up of 2 years, there were 133 events in the Herceptin group and 261 in the control group, a statistically significant difference. Herceptin reduced the mortality rate by one third, the authors note.

As in the HERA study, there was an increased rate of congestive heart failure associated with Herceptin. "Clearly, appropriate selection and careful cardiac monitoring of patients are essential," Geyer's group indicates.

These results are "simply stunning," and "not evolutionary but revolutionary," Dr. Gabriel N. Hortobagyi, from the University of Texas M. D. Anderson Cancer Center in Houston, states in a related editorial. "With very brief follow-up...all three trials show highly significant reductions in the risk of recurrence, of a magnitude seldom observed in oncology trials."

SOURCE: The New England Journal of Medicine, October 20, 2005.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underBreast Cancer
Cancer

Strong social ties benefit breast cancer patients

Breast cancer patients who have a strong social support system in the first year after diagnosis are less likely to die or have a recurrence of cancer, according to new research from Vanderbilt-Ingram Cancer Center…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.